RAD 140 - Radius Health

Drug Profile

RAD 140 - Radius Health

Alternative Names: RAD-140

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Radius
  • Developer Radius; Radius Health Inc.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • No development reported Muscular atrophy; Osteoporosis

Most Recent Events

  • 29 Sep 2017 Phase-I clinical trials in Breast cancer (Metastatic disease) in USA (PO) (NCT03088527)
  • 03 Aug 2017 US FDA accepted an IND application submitted by Radius Health for Breast cancer
  • 24 Feb 2017 Radius Health has patent protection for RAD 140 in USA, Australia, Canada, Europe, Japan and Mexico (Radius Health's form 10-K, filed in February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top